Comparative Pharmacology
Head-to-head clinical analysis: MINOXIDIL FOR WOMEN versus TRANSDERM NITRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINOXIDIL FOR WOMEN versus TRANSDERM NITRO.
MINOXIDIL (FOR WOMEN) vs TRANSDERM-NITRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minoxidil is a potassium channel opener. It activates ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arterioles, causing peripheral vasodilation and reduced blood pressure. For hair growth, the exact mechanism is unclear but involves increased cutaneous blood flow, stimulation of hair follicle proliferation via direct effects on dermal papilla cells, and prolongation of the anagen phase.
Nitroglycerin is converted to nitric oxide (NO), which activates guanylate cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
Topical: 2% or 5% solution, 1 mL applied to the scalp twice daily (morning and evening).
Initial dose 0.2-0.4 mg/hour transdermally once daily. Titrate to 0.4-0.8 mg/hour. Maximum 0.8 mg/hour.
None Documented
None Documented
Terminal elimination half-life: approximately 4.2 hours in patients with normal renal function; may extend to 24+ hours in renal impairment.
Terminal elimination half-life is approximately 1-4 minutes after IV administration due to rapid metabolism. After transdermal application, the apparent half-life is 3-4 hours due to continued absorption from the skin depot, resulting in a prolonged clinical effect.
Primarily renal (90% as unchanged drug and metabolites; 10% via feces via biliary elimination).
Renal (primarily) and biliary; ~60-80% of the dose is excreted renally as metabolites, with <1% unchanged. Fecal excretion accounts for ~10-20%.
Category A/B
Category C
Vasodilator / Hair Growth Stimulant
Vasodilator